At DxPx US, PBD Biotech was one of the eight innovative, early-stage companies participating in the finals of the 42PLUS1 Pitch Competition. We thoroughly enjoyed participating and it put our Actiphage TB blood test in front of an audience of potential investors and collaborators.
The company has now been selected to go forward to the final at DxPx EU in Munich.
Jonnie Yewdall, Chief Commercial Officer, comments: “DxPx EU promises to be a great insight into ground-breaking ideas in the diagnostics, life sciences and healthcare industries and an opportunity for us to profile Actiphage again to interested parties.”
“One of our goals is to investigate and integrate platforms that allow automation of some, or all the processes involved in Actiphage TB.
“This includes evaluation of methods that would allow us to streamline the various test steps, from isolation of the PBMCs in the whole blood, to handling the phage incubation step and purification of DNA, ready for downstream qPCR, NGS, or digital PCR analysis, increasing throughput and allowing scale-up of the Actiphage TB Blood Test delivery.
If you are planning to be at DxPx EU please contact us to arrange a meeting.
DxPx Eu is to be held Oct. 5, 2023, Leonardo Royal Munich, Germany.